|Bid||31.10 x 800|
|Ask||32.27 x 1100|
|Day's Range||31.78 - 32.68|
|52 Week Range||28.58 - 61.69|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Progress continues on the company's work to develop a mental health treatment using a psychoactive drug therapy.
Clinical trial results expected this fall could send shares of these stocks screaming higher, or lower.
Innovation in the pharmaceutical industry has never been more exciting than it is right now, and there are some excellent companies that could be big winners for patient investors. In this Fool Live clip, recorded on Sept. 15, Fool.com contributor Jason Hall explains to Senior Analyst Asit Sharma why Compass Pathways (NASDAQ: CMPS) in particular is on his watch list now. Jason Hall: This is something that I'm going to talk about.